Globus Medical (GMED) vs ResMed (RMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Globus Medical (GMED) has outperformed ResMed (RMD) over the past year, gaining 21.4% versus a loss of 19.7%. Over five years, GMED leads with a -4.1% price change compared with -11.3% for RMD. ResMed is the larger company by market cap ($32.35 billion vs $10.02 billion), about 3.2 times the size, while Globus Medical is growing revenue faster (+16.7% vs +9.9%).
On valuation, Globus Medical trades at a lower forward P/E (13.8x vs 17.4x for ResMed). ResMed pays a dividend yielding 1.04%, while Globus Medical does not currently pay one. ResMed converts more of its revenue into profit, with a net margin of 26.9% versus 18.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GMED | RMD |
|---|---|---|
| Share price | $74.65 | $230.05 |
| Market cap | $10.02B | $32.35B |
| 1-day change | +1.80% | +1.46% |
| YTD return | -16.01% | -5.87% |
| 1-year return | +21.37% | -19.70% |
| 5-year return | -4.06% | -11.26% |
| P/E ratio (TTM) | 19.14 | 22.06 |
| Forward P/E | 13.83 | 17.39 |
| EPS (TTM) | $3.90 | $10.43 |
| Dividend yield | 0.00% | 1.04% |
| Annual dividend | $0.00 | $2.40 |
| Revenue (latest FY) | $2.94B | $5.65B |
| Revenue growth (YoY) | +16.65% | +9.85% |
| Net income (latest FY) | $537.87M | $1.52B |
| Gross margin | 67.41% | 61.06% |
| Operating margin | 16.33% | 33.37% |
| Net margin | 18.30% | 26.94% |
| 52-week high | $101.40 | $277.85 |
| 52-week low | $56.50 | $180.27 |
| Distance from 52-week high | -26.38% | -17.20% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +35.19% | +8.77% |
| Average volume | 1.51M | 1.33M |
| Shares outstanding | 111.83M | 140.64M |
| Employees | 6,000 | 11,370 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ResMed is about 3.2 times larger than Globus Medical by market value ($32.35B vs $10.02B).
- GMED has outperformed RMD by 41.1 percentage points over the past year.
- ResMed offers a meaningfully higher dividend yield (1.04% vs 0.00%).
- ResMed is more profitable, keeping 26.9 cents of every revenue dollar as net income versus 18.3 cents for Globus Medical.
- Globus Medical grew revenue faster in its latest fiscal year (+16.65% vs +9.85%).
About Globus Medical
GMED stock →Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.
Health Care · Medical/Dental Instruments · 6,000 employees
About ResMed
RMD stock →ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally.
Health Care · Medical/Dental Instruments · 11,370 employees
GMED vs RMD FAQ
Which is bigger, Globus Medical or ResMed?
ResMed (RMD) is larger, with a market capitalization of $32.35B compared with $10.02B for Globus Medical (GMED).
Which stock has performed better over the past year, GMED or RMD?
GMED returned +21.37% over the past 12 months, compared with -19.70% for RMD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, GMED or RMD?
GMED has the lower trailing P/E at 19.1, versus 22.1 for RMD. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Globus Medical or ResMed?
ResMed pays a dividend yielding 1.04%, while Globus Medical does not currently pay a regular dividend.
Are Globus Medical and ResMed in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.